Medical News

RSS

Study finds increase in cervical cancer incidence among young British women

The incidence of cervical cancer in women in their 20s has risen by over 40 per cent between 1992 and 2006 in England, despite the overall incidence of cervical cancer dropping by 30 per cent, according to research that will be presented at the annual National Cancer Research Institute (NCRI) Cancer Conference in Liverpool which starts tomorrow.

5 Nov 2011

VA announces 13 new awards in 2010 Industry Innovation Competition

The Department of Veterans Affairs today announced 13 new awards in the agency's 2010 Industry Innovation Competition. The new projects will give VA an opportunity to evaluate new ways to enhance care and benefits for Veterans.

5 Nov 2011

Tenet to sell $750 million senior secured notes due 2018

Tenet Healthcare Corporation announced today that it is offering to sell $750 million aggregate principal amount of senior secured notes maturing in 2018 through a private placement.

5 Nov 2011

Pall launches new Acrodisc MS syringe filter

Pall Corporation, today introduced the Pall Acrodisc MS Syringe Filter the first syringe filter certified for low extractables in high performance liquid chromatography/mass spectrometry (LCMS) applications.

From Pall Corporation 5 Nov 2011

Education for women, girls a more effective strategy than family planning to solve global problems

In a post in the National Review's "The Corner," Christopher White, international director of operations for the World Youth Alliance, responds to a New York Times opinion piece published Wednesday in which columnist Nicholas Kristof hailed family planning as a solution to "many of the global problems that confront us."

5 Nov 2011

EES closes transaction to acquire SterilMed

Ethicon Endo-Surgery, Inc. (EES), a global leader in the development of innovative medical devices for minimally invasive and open surgical procedures, today announced the closing of the transaction to acquire SterilMed, Inc. (SterilMed), a leader in the reprocessing and remanufacturing of single-use medical devices in the United States.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

American Vanguard third quarter net sales increase 8% to $73.8 million

American Vanguard Corporation, today announced financial results for the third quarter and nine month period ended September 30, 2011.

5 Nov 2011

Smile Brands announces opening of Bright Now! Dental office in Tampa

Smile Brands Inc., the nation's leading provider of business support services to dental groups in the United States, today announced the grand opening of its newest Bright Now! Dental office in Tampa, FL. This new office marks the 25th office in the state of Florida.

5 Nov 2011

New UBC technology can accurately detect brain aneurysms

University of British Columbia researchers have developed new technology for monitoring brain aneurysms - an approach that is potentially less invasive and more accurate than current methods, and one that is simple enough for patients to use at home for frequent monitoring.

5 Nov 2011

Idera raises $9.5M in convertible preferred stock offering

Idera Pharmaceuticals, Inc. today announced it has raised $9.5 million in a convertible preferred stock offering.

5 Nov 2011

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

Helix Biomedix third quarter revenue increases 321% to $395,000

Helix BioMedix, Inc., a developer of bioactive peptides, today announced financial results for the company's third quarter ended September 30, 2011.

5 Nov 2011

Viewpoints: Romney's plan to cut the debt; congressional squabbles on spending; spurning insurers' concerns about new labels

First, eliminate every government program that is not absolutely essential. There are many things government does that we may like but that we do not need. … For example: Repeal ObamaCare, which would save $95 billion in 2016. …Eliminate Title X family planning programs benefiting abortion groups like Planned Parenthood. … Second, return federal programs to the states where innovation, cost management and reduction of fraud and abuse can far exceed what Washington achieves. I will block grant Medicaid and workforce training, saving well over $100 billion in 2016.

5 Nov 2011

MicroRNAs may predict risk of recurrence in post-resection gastric cancer patients

Rosetta Genomics, Ltd., a leading developer and provider of microRNA-based molecular diagnostics, announces that results from a joint study by researchers at the Institutes of Oncology, Davidoff Center, Rabin Medical Center, Beilinson Hospital and Golda-Hasharon Hospital in Petach-Tikva, Israel show that in post-resection gastric cancer patients microRNAs may serve to predict the risk of recurrence.

4 Nov 2011

Osiris Therapeutics third quarter revenues decrease marginally to $10.6 million

Osiris Therapeutics, Inc., the leading stem cell company focused on developing and marketing products to treat medical conditions in inflammatory and cardiovascular disease areas and wound healing, announced today its results for the third quarter ended September 30, 2011.

4 Nov 2011

Experts look to India to develop accurate, affordable TB diagnostics

SciDev.Net examines tuberculosis (TB) in India, which has the world's highest TB burden, and some experts' hopes that researchers in the country can develop accurate and affordable diagnostic test kits.

4 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Psychotherapy could have diverse cerebral effects depending on certain genes

Problems like anxiety and depression are caused by psychological and environmental factors, and are known to be influenced by genetic proclivities. However, it is still not clear how each factor affects the brain's functions to induce anxious and depressive symptoms.

4 Nov 2011

Global Fund releases additional audits as part of internal investigation

The Global Fund to Fight AIDS, Tuberculosis and Malaria on Tuesday posted the results of several internal audits, showing "that 12 more probes had turned up an additional $20 million of mismanagement, alleged fraud and misspending," the Associated Press/CBSNews.com reports.

4 Nov 2011